# Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

> **NCT01558661** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** AG-013736 (AXITINIB)

## Key facts

- **NCT ID:** NCT01558661
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-11-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01558661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01558661, "Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01558661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*